Amyotrophic Lateral Sclerosis Archives - Express Pharma

Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

ALS market across 8MM set to reach $1.28 bn in 2029: GlobalData

Gland Pharma receives USFDA approval for Edaravone Injection

WHO INN approves ‘Usnoflast’ as recommended name for ZYIL1 from Zydus

Coya, Dr Reddy’s sign pact to develop and market COYA 302 for treatment of ALS

Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS

Global ALS market may grow to $1.04 bn in 2029 driven by anticipated drug launches

IIT Hyderabad researchers find new molecule to potentially treat Amyotrophic Lateral Sclerosis